bengaluru december biocon breast gastric cancer drug ogivri developed association pharma company mylan became first ever indian biosimilar drug approved sale u republic of india long world drawing card developing generic drugs chemically produced dose almost exact copies drugs occasionally still patent manufactured generic wine public good biocon success us intas pharma earlier success europe biosimilar treat immune system disorders suggest india developing strengths biosimilars unlike generics biosimilars biologic products made inside live cells though clinical differences terms safety effectiveness original product impossible manufacture exact written matter biotech drugs hence word similar past two years biocon date several world successes biosimilar insulin glargine launched japan july massive contract biosimilar malaysia wellness ministry january country first locally manufactured biosimilar breast gastric cancer drug approvals us brazil december pushed biocon stock memorialize levels shares rising last year scrip valued roentgen beginning closed rs bse monday interaction toi biocon founder chairperson md kiran said biosimilars would start contributing revenue next fiscal twelvemonth company would touch 1000000000 revenue year company year operation bring next billion easier said excerpts interview difficult making biosimilar compared chemical molecule generic molecules chemically synthesised wellfixed make copy biologically produced molecules latter protein complex large molecule put perspective small molecule generics pin head protein like big symbol made complex fact collection peptides body make proteins perform many functions shape certain ways know body mimicking protein tough protein produced externally different conditions never source similar pauperism high understanding biological science biological scientific discipline understand indian pharma companies shied away making biosimilars indian pharma chemical synthesis mastered stay away investing biologics complex expensive biologics need set separate infrastructure spend huge research development r use different kinds equipment confirmation integrity proteins analysis among first years starting biocon turn good building enzymes enzyme nothing proteins enzymes meticulous utilize industrial additive organic accelerator break amylum glucose fatten up fatty acid get challenge biopharmaceuticals human protein coordination compound belong immune system of rules metabolic system endocrine system interesting group scientists immunologists biologists geneticists protein chemists bioinformaticians together look protein address integrity protein see close original human protein make recombinant human insulin completely mimic insulin produced body similarly make antibody india excellent much investment needed realise biosimilars compared generics much expensive made sterile conditions generic done 6 months biosimilar lease five old age still guarantee approved regulators around globe takes million develop generic molecule biosimilar costs anywhere million one thousand thousand pharma company would rather small atom rather one biosimilar aspirin cost paise biosimilar would toll rs biologics answer cancer globally slue among big pharma companies move biologics small corpuscle cure diseases treated chemical pipeline consists biologics large number cancers curable immunotherapy attacks specific cells turned malignant immunotherapy biologic therapy type cancer treatment boosts body natural defences fight malignant neoplastic disease cell hz cell born grows dies cell death take place keeps duplicating becomes tumour soundbox unable recognize strange phenomenon mobile phone fools dead body consider part natural process creating certain hormones ways discover tumour kill chemotherapy bombard cells poison kill trouble completely defeat someplace cell growing